Skip to main content
Premium Trial:

Request an Annual Quote

Access Inks Delivery Technology-Evaluation Deal with Undisclosed Pharma

Premium

Access Pharmaceuticals this week announced that it has signed a deal under which its CobaCyte and CobOral siRNA delivery technologies will be evaluated by an undisclosed pharmaceutical company.

The delivery approaches are based on Access' so-called Cobalamin technology, which takes advantage of the body's natural vitamin B12-uptake mechanism. A polymer and an siRNA are joined to make a nanoparticle, which is then coated with the vitamin.

According to Access, it will provide oral and intravenous siRNA formulations to the pharmaceutical firm for evaluation.

Successfully developed compounds will be subject to a formal licensing agreement, Access noted.

Additional terms were not disclosed. The deal follows a similar arrangement Access forged earlier in the year (GSN 4/14/2011).

The Scan

Billion-Dollar Diversity Initiative

The Howard Hughes Medical Institute is now accepting applications for its new $1.5 billion initiative to boost the diversity of the scientific workforce.

Biotech Co-Founder Arrested

A co-founder of a Los Angeles-based biotech company has been arrested in connection with a murder-for-hire scheme, according to Endpoint News.

Return of the Tasmanian Tiger

The Washington Post reports that a team in Australia is working to bring the thylacine back from extinction.

Nature Papers on Genome of Individual From Pompeii, CircRNA Study Best Practices, More

In Nature this week: first sequenced genome of a person from Pompeii, best practice guidelines for circRNA studies, and more.